<?xml version="1.0" encoding="UTF-8"?>
<p id="p0155">The antiviral medications target several components of the SARS-CoV-II lifecycle. These molecular targets include the viral entry into the host cells, the viral RNA synthesis, and the viral replication [
 <xref rid="bb0560" ref-type="bibr">112</xref>]. There are high sequence similarities in the genomes of SARS-CoV-II, SARS-CoV, and MERS-CoV. It is possible for the shared effectiveness of the previously approved medications in these conditions for the treatment of COVID-19.
</p>
